STADA is expanding its European Consumer Healthcare portfolio by acquiring another range of well-established local and regional consumer healthcare brands from Sanofi in European countries, including Belgium, Germany, Hungary, Spain and the United Kingdom, as well as Nordic countries.
The transaction covers several brands, including: Antistax for pain relief and tiredness in legs; the allergy eye drops Lomudal; Omnivit vitamins; and Opticrom allergy eye drops. In addition, the two painkillers AAS and Dolalgial, as well as Bila-Git for gallbladder complaints, are part of the acquired portfolio.
“We are pleased to continue our collaboration with Sanofi. This acquisition further strengthens STADA as a top-four player in Europe’s consumer healthcare market and supports our growth acceleration along our purpose of ‘Caring for People’s Health as a Trusted Partner’,” said STADA’s CEO, Peter Goldschmidt.
“As a broad-based European player with a strong presence in local markets, STADA is a go-to partner in consumer healthcare,” Goldschmidt highlighted. “The brands being acquired, and their geographic presence, are well aligned and synergistic with the organic activities in STADA’s core countries.”
STADA’s Western Europe and Germany head Stephan Eder said: “This acquisition is the next step towards being the leader in local market brands. STADA’s extensive sales, marketing and distribution network throughout Europe, along with our long-established partnerships with pharmacists, will enable the group to grow these brands by also developing additional offerings.
“By further developing these well-known brands, we are strengthening our compelling and comprehensive offering to customers across our three strategic pillars: Consumer Healthcare, Specialty and Generics in key, predominantly Western European countries.”
This acquisition was preceded by a transaction for 16 brands from Sanofi in 2021, as well as an agreement with Sanofi about the distribution of Sanofi’s consumer healthcare portfolio in 10 countries in Central Asia in 2022.